Back to
Axxcess Wealth Management, LLC
HALO
2 quarters
Position history for
Axxcess Wealth Management, LLC's holdings in Halozyme Therapeutics, Inc.
No. Axxcess Wealth Management exited its HALO (Halozyme Therapeutics) position in Q1 2023. Its Q4 2022 13F listed 3,950 shares worth $224,755. Axxcess Wealth Management first reported HALO in Q4 2022 and held it in 1 quarterly 13F filing.
Final Value
$0
Final Shares
0
Total Value Change
-$224,755
Total Shares Change
-3,950
Quarter-by-Quarter History
Other major holders of HALO: BlackRock, Inc., BlackRock Finance, Inc.